BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

After Capturing the U.S. Market, Frost & Sullivan Recognizes Naviscan, Inc.'s Pioneering Organ-Specific PET Scanner's Potential in Europe


6/5/2012 11:44:15 AM

MOUNTAIN VIEW, Calif. — June 6, 2012 — Based on its recent analysis of the organ-specific molecular imaging market, Frost & Sullivan recognizes Naviscan Inc. (Naviscan) with the 2012 European Frost & Sullivan Award for Product Quality Leadership for its organ-specific PET scanner. With its main application in Positron Emission Mammography (PEM), the product offers multiple benefits to the customer over competing products.

Naviscan’s PET scanner offers numerous advantages in a wide variety of clinical applications, such as detection, staging, monitoring response to neo-adjuvant chemotherapy and re-staging of breast cancer, detection of peripheral tumors, and screening for recurrent melanoma. Applications that are showing promise in ongoing clinical trials include osteoarthritis and rheumatoid arthritis. With its ability to position the detectors in close proximity to the organ imaged—achieving higher resolution than a whole-body (WB) PET scanner—the product is simply superior in quality.

Naviscan’s intelligent design, including advanced photonics, biopsy guidance software and cutting-edge visualization software, MIMViewer TM PEM workstation, which was developed by MIMvista Software™, helps deliver high-quality 3D tomographic images with excellent spatial resolution. While the existing conventional screening methods for breast cancer produce results of 80 to 91 percent sensitivity, PEM offers 93 percent sensitivity and 93 percent specificity. The visualization software is characteristic of its user-friendly interface with options for creating customized images with attention to regions of interest that can be saved as DICOM files to any PACS system.

“The proven accuracy, high sensitivity and specificity of the scanner in the detection of lesions, particularly for breast cancer, helps the physicians make confident and informed diagnosis,” said Frost & Sullivan Research Analyst Kaavya Karunanithi. “This helps in eliminating the number of false positives that lead to unnecessary biopsies.”

Further, the compact nature of the product offers additional economic benefits by reducing maintenance and installation charges when compared to WB PET or MRI scanners. Naviscan’s design team has made the PET scanner very portable to enable remote diagnostics.

“The company’s major focus on quality in the past five years has enabled its PET scanner to achieve high market penetration in the USA by capitalizing on numerous peer-reviewed publications from multicenter prospective clinical trials that showcase the high sensitivity, specificity and accuracy that the product delivers,” notes Karunanithi. “It is with this reputation that the product aims to capture the European market.”

The product is endorsed by the FDA and has a CE mark for its high-quality compliance, so it is certain to achieve the market leadership position in organ-specific molecular imaging in Europe in the near future. Naviscan introduced initial installations in Turkey and Germany in 2011. There are also orders for installations in Spain and Switzerland, and a strong pipeline of opportunities across Europe for 2012.

Overall, Naviscan’s organ-specific PET scanner, due to its high sensitivity, high specificity and accuracy, complements conventional imaging methods, such as mammography or ultrasound, and is a research-proven alternative to MRI. In recognition, Frost & Sullivan is proud to present Naviscan with the 2012 European Frost & Sullivan Award for Product Quality Leadership in the organ-specific molecular imaging market.

Each year, Frost & Sullivan presents this award to the company that has demonstrated outstanding product performance and value to customers. The award recognizes significant contribution in terms of design, usability and reliability.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Naviscan

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world. and has global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation, including: research, analysis, strategy, vision, innovation and implementation.

• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact:

Mireya Espinoza

P: 210. 247.3870

F: 210.348.1003

E: mireya.espinoza@frost.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES